Literature DB >> 23699599

Outcomes of patients with POEMS syndrome treated initially with radiation.

Michael S Humeniuk1, Morie A Gertz, Martha Q Lacy, Robert A Kyle, Thomas E Witzig, Shaji K Kumar, Prashant Kapoor, John A Lust, Suzanne R Hayman, Francis K Buadi, S Vincent Rajkumar, Steven R Zeldenrust, Stephen J Russell, David Dingli, Yi Lin, Nelson Leung, Angela Dispenzieri.   

Abstract

POEMS syndrome is a rare plasma cell dyscrasia presenting with polyneuropathy and other systemic findings. Patients with 1 to 3 bone lesions and negative bone marrows are often treated with involved field radiation therapy as the initial and potentially definitive therapy. Long-term outcomes of patients treated with this approach have not been systematically studied. Of the 146 patients with POEMS syndrome seen at the Mayo Clinic between January 1999 and September 2011, 38 (26%) were given targeted radiation as their initial primary therapy and are the ones studied here. The median number of bone lesions was 1 (range: 1-6). The median dose of radiation administered was 45 Gy (range: 35-54 Gy). Complete or partial hematologic, vascular endothelial growth factor, fluorodeoxyglucose-positron emission tomography, and clinical responses were documented in 31%, 14%, 22%, and 47%, respectively. With median follow-up of 43 months, the 4-year overall survival is 97% and event-free survival is 52%. Risk factors for needing salvage therapy included reduced pulmonary diffusing capacity of carbon monoxide and increased urinary total protein. The presence of 3 lesions compared with 1 or 2 did not increase risk for treatment failure. Among selected patients with POEMS syndrome, radiation produces durable, meaningful responses.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23699599      PMCID: PMC4067496          DOI: 10.1182/blood-2013-03-487025

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  24 in total

1.  Guidelines on the diagnosis and management of solitary plasmacytoma of bone and solitary extramedullary plasmacytoma.

Authors:  Richard Soutar; Helen Lucraft; Graham Jackson; Anthony Reece; Jenny Bird; Eric Low; Diana Samson
Journal:  Clin Oncol (R Coll Radiol)       Date:  2004-09       Impact factor: 4.126

2.  Solitary plasmacytoma of bone: Mayo Clinic experience.

Authors:  D A Frassica; F J Frassica; M F Schray; F H Sim; R A Kyle
Journal:  Int J Radiat Oncol Biol Phys       Date:  1989-01       Impact factor: 7.038

3.  Myeloma neuropathy. Successful treatment of two patients and review of cases.

Authors:  L E Davis; D B Drachman
Journal:  Arch Neurol       Date:  1972-12

4.  Solitary plasmacytoma of bone and soft tissue.

Authors:  T W Bolek; R B Marcus; N P Mendenhall
Journal:  Int J Radiat Oncol Biol Phys       Date:  1996-09-01       Impact factor: 7.038

5.  Osteosclerotic myeloma with polyneuropathy.

Authors:  J B Reitan; E Pape; S D Fosså; O J Julsrud; O N Slettnes; O P Solheim
Journal:  Acta Med Scand       Date:  1980

6.  The relation between chronic polyneuropathy and osteosclerotic myeloma.

Authors:  J B Morley; A C Schwieger
Journal:  J Neurol Neurosurg Psychiatry       Date:  1967-10       Impact factor: 10.154

7.  Outcomes and patterns of failure in solitary plasmacytoma: a multicenter Rare Cancer Network study of 258 patients.

Authors:  Mahmut Ozsahin; Richard W Tsang; Philip Poortmans; Yazid Belkacémi; Michel Bolla; Fazilet Oner Dinçbas; Christine Landmann; Bernard Castelain; Jeroen Buijsen; Jürgen Curschmann; Sidney P Kadish; Anna Kowalczyk; Yavuz Anacak; Josef Hammer; Tan D Nguyen; Gabriela Studer; Rachel Cooper; Meriç Sengöz; Luciano Scandolaro; Abderrahim Zouhair
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-10-17       Impact factor: 7.038

8.  Solitary bone plasmacytoma: outcome and prognostic factors following radiotherapy.

Authors:  R H Liebross; C S Ha; J D Cox; D Weber; K Delasalle; R Alexanian
Journal:  Int J Radiat Oncol Biol Phys       Date:  1998-07-15       Impact factor: 7.038

9.  Radiation therapy in multiple myeloma.

Authors:  W B Mill
Journal:  Radiology       Date:  1975-04       Impact factor: 11.105

10.  Polyneuropathy, skin hyperpigmentation, edema, and hypertrichosis in localized osteosclerotic myeloma.

Authors:  H Iwashita; A Ohnishi; M Asada; Y Kanazawa; Y Kuroiwa
Journal:  Neurology       Date:  1977-07       Impact factor: 9.910

View more
  15 in total

1.  Polyneuropathy improvement following autologous stem cell transplantation for POEMS syndrome.

Authors:  Chafic Karam; Christopher J Klein; Angela Dispenzieri; P James B Dyck; Jay Mandrekar; Anita D'Souza; Michelle L Mauermann
Journal:  Neurology       Date:  2015-04-15       Impact factor: 9.910

2.  Computed tomography assessment of bone lesions in patients with POEMS syndrome.

Authors:  K Glazebrook; Francis L Guerra Bonilla; Adam Johnson; S Leng; A Dispenzieri
Journal:  Eur Radiol       Date:  2014-09-25       Impact factor: 5.315

3.  Radiotherapy for the treatment of solitary plasmacytoma: 7-year outcomes by a mono-institutional experience.

Authors:  Alessandro Alghisi; Paolo Borghetti; Marta Maddalo; Aldo Maria Roccaro; Alessandra Tucci; Rosario Mazzola; Stefano Maria Magrini; Antonio Lo Casto; Marco Lorenzo Bonù; Davide Tomasini; Nadia Pasinetti; Gloria Peretto; Francesco Bertagna; Cesare Tomasi; Michela Buglione; Luca Triggiani
Journal:  J Cancer Res Clin Oncol       Date:  2020-11-17       Impact factor: 4.553

Review 4.  Advances in the Treatment of Paraproteinemic Neuropathy.

Authors:  Eduardo Nobile-Orazio; Mariangela Bianco; Andrea Nozza
Journal:  Curr Treat Options Neurol       Date:  2017-10-16       Impact factor: 3.598

5.  POEMS (Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Protein, and Skin Changes): A Case Report of a Rare Paraneoplastic Syndrome.

Authors:  Anuradha Sakhuja; Dhan B Shrestha; Wasey Ali Yadullahi Mir; Suman Gaire; Mohammed Kassem
Journal:  Cureus       Date:  2022-05-13

6.  Prognostic study for overall survival in patients with newly diagnosed POEMS syndrome.

Authors:  C Wang; X-F Huang; Q-Q Cai; X-X Cao; M-H Duan; H Cai; D-B Zhou; J Li
Journal:  Leukemia       Date:  2016-06-13       Impact factor: 11.528

7.  Risk factors for and outcomes of patients with POEMS syndrome who experience progression after first-line treatment.

Authors:  T V Kourelis; F K Buadi; M A Gertz; M Q Lacy; S K Kumar; P Kapoor; R S Go; J A Lust; S R Hayman; V Rajkumar; S R Zeldenrust; S J Russell; D Dingli; Y Lin; N Leung; Y L Hwa; W Gonsalves; R A Kyle; A Dispenzieri
Journal:  Leukemia       Date:  2015-12-16       Impact factor: 11.528

Review 8.  POEMS Syndrome: an Enigma.

Authors:  Rahma Warsame; Uday Yanamandra; Prashant Kapoor
Journal:  Curr Hematol Malig Rep       Date:  2017-04       Impact factor: 4.213

9.  Pathological Fracture Caused by Vascular Endothelial Cell Hemangioma-like Hyperplasia in POEMS Syndrome.

Authors:  Jie Fang; LiXia Sun; JinQiao Zhang
Journal:  Am J Med Sci       Date:  2015-06       Impact factor: 2.378

10.  The role of radiotherapy in the management of POEMS syndrome.

Authors:  Yang-Gun Suh; Young-Suk Kim; Chang-Ok Suh; Yu Ri Kim; June-Won Cheong; Jin Seok Kim; Jaeho Cho
Journal:  Radiat Oncol       Date:  2014-11-28       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.